Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$86.88 USD
+2.51 (2.97%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $86.88 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.88 USD
+2.51 (2.97%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $86.88 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Glaxo's Shingles Candidate Gets Positive FDA Committee Vote
by Zacks Equity Research
Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients.
Pfizer Lung Cancer Drug's Overall Survival Data Unfavorable
by Zacks Equity Research
Pfizer (PFE) announced final overall survival data from a phase III study (PROFILE 1014), evaluating its cancer drug Xalkori for first-line treatment of ALK-positive non-small cell lung cancer (NSCLC).
5 Top-Ranked Biotech Stocks to Buy Right Now
by Arpita Dutt
If you are looking to invest in the biotech sector, here is a peek at 5 buy-ranked biotech stocks including Regeneron Pharmaceuticals (REGN).
Lilly to Cut 3,500 Jobs to Invest in New Drugs and Growth
by Zacks Equity Research
Lilly (LLY) plans to reduce its global workforce by approximately 3,500 positions, which should save $500 million. Lilly plans to invest the savings in new drugs and overall growth of the company.
Alnylam Shares Plunge on Patient Death, Dosing Suspended
by Zacks Equity Research
Alnylam (ALNY) announced suspension of dosing in all ongoing studies on its hemophilia candidate, fitusiran, following a patient's death in a phase II study.
Ligand (LGND) Up 9.6% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand (LGND) Diabetes Candidate Positive in Phase II Study
by Zacks Equity Research
Ligand's (LGND) diabetes candidate, LGD-6972, demonstrated a change of statistical significance in blood glucose level (HbA1c) from baseline over a treatment period of 12 weeks.
Insmed Incorporated (INSM) Catches Eye: Stock Soars 119.6%
by Zacks Equity Research
Insmed Incorporated (INSM) was a big mover last session, as the company saw its shares rise nearly 120% on the day amid huge volumes.
Biotech Stock Roundup: Cellectis Down on Clinical Hold, Insmed Soars on Positive Data
by Arpita Dutt
Key highlights include pipeline updates from companies like Cellectis (CLLS) and Insmed. Insmed's shares skyrocketed on positive data from a late-stage study.
Amgen Gets EU Nod to Expand Hyperparathyroidism Drug Label
by Zacks Equity Research
The European Commission approves Amgen's (AMGN) marketing application for Mimpara's pediatric formulation to heal secondary hyperparathyroidism (HPT).
Top Ranked Momentum Stocks to Buy for August 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 30th:
3 Reasons Why Ligand Pharmaceuticals (LGND) is a Great Momentum Stock
by Zacks Equity Research
Momentum Stock Investors Will Love Ligand Pharmaceuticals (LGND) seeing its favorable price performance both in short and long term.
Vertex's Cystic Fibrosis Combo Gets Priority Review in U.S.
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) regulatory applications for tezacaftor/ivacaftor (Kalydeco) combination have been accepted by the FDA and EMA for review.
Strength Seen in Myovant Sciences (MYOV): Stock Soars 16.1%
by Zacks Equity Research
Myovant Sciences Ltd. (MYOV) was a big mover last session, as the company saw its shares rise over 16% on the day.
Can Ligand's Captisol Deals Boost Growth in the Long Run?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, earning milestones and royalty payments from the same.
Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised
by Zacks Equity Research
Ligand's (LGND) earnings and revenues beat estimates. Total revenue also rises year over on the back of higher royalty benefits. The company ups its outlook for 2017.
Can Ligand (LGND) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.
Ligand Signs Agreement with Amgen, Grants Rights to Captisol
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announced that it has signed a commercial license and supply agreement with Amgen Inc. granting exclusive worldwide rights to use Ligand's Captisol technology for the development of AMG 330
Ligand Gets Milestone Payment on Partner Drug FDA Approval
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announced receipt of a milestone payment of $1.5 million after its partner Melinta Therapeutics' pipeline candidate Baxdela (delafloxacin) was approved by the FDA.
Why Is Ligand Pharmaceuticals (LGND) Up 5.1% Since the Last Earnings Report?
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Key FDA Events to Watch Out for in Jun 2017
by Arpita Dutt
Companies like Portola (PTLA) are awaiting key FDA decisions this month which could send their stocks soaring in case of a positive response.
Ligand (LGND) Signs Licensing Deal with xCella Biosciences
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) announces it has entered into a worldwide license agreement with drug discovery company xCella Biosciences, Inc.
Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) reported first-quarter 2017 earnings of 31 cents per share (including the impact of stock-based compensation expenses), down 32.5% from the year-ago figure.
Can Ligand (LGND) Spring a Surprise this Earnings Season?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report first-quarter 2017 results on May 9, after the market closes.
New Strong Sell Stocks for March 7th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: